Attached files
| file | filename |
|---|---|
| 8-K - 8-K - PDL BIOPHARMA, INC. | pdli-20140303x8xkdoc.htm |
| EX-99.2 - PRESENTATION - PDL BIOPHARMA, INC. | pdli-20140303x8xkex992.htm |
| EX-99.1 - PRESS RELEASE - PDL BIOPHARMA, INC. | pdli-20140303x8xkex991.htm |
Exhibit 99.3
PDL BioPharma, Inc.
Q4-Year End 2013
March 3, 2014
Following are some of the key points regarding PDL’s fourth quarter and full year 2013 financial and business results.
Net Income
• | Net income in 2013 was $264.5 million, or $1.66 per diluted share, as compared with net income in 2012 of $211.7 million, or $1.45 per diluted share. Net income for the fourth quarter of 2013 was $61.1 million, or $0.39 per diluted share, as compared with net income of $49.4 million for the same period of 2012, or $0.34 per diluted share. The increase in net income in the fourth quarter is primarily due to a 27 percent increase in royalty revenues, which included royalty revenues related to the first two months of Glumetza royalties from Depomed. |
2014 Dividends
• | On January 29, 2014, PDL’s Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 12, June 12, September 12 and December 12 of 2014 to all stockholders who own shares of PDL on March 5, June 5, September 5 and December 5 of 2014, the record dates for each of the dividend payments, respectively. On December 12, 2013, PDL paid the fourth quarterly dividend to stockholders of record totaling $21.0 million using earnings generated in the fourth quarter of 2013. |
Board Decision to Continue Operations
• | PDL’s board of directors, having evaluated the operational and financial results and forecasts of the Company, as well as the successes to date in acquiring income generating assets, has made the strategic decision to continue its operations post expiration of the Queen et al. patents and to continue the strategy of pursuing new income generating assets so as to extend its ability to pay dividends to its shareholders. |
Settlement Agreement with Genentech/Roche
• | In January, we reached an agreement with Roche and Genentech to resolve all outstanding legal disputes between us. We are pleased with the outcome and believe that our shareholders benefit from this settlement given that the royalty rate reflects an increase over historical rates, and there is now certainty around the period for which we will continue to receive royalties. Further details can be found in the earnings release or 10-K. |
Reduction of Principal in Existing 2.875% Convertible Notes (Feb 2015)
• | In February, we entered into exchange and purchase agreements for approximately $131.7 million of principal outstanding of the 2.875% Convertible Notes due in February 2015 in return for 20.3 million shares and $34.2 million in cash. The effect of this transaction is to reduce the principal outstanding from approximately $180 million to about $48 million. One of the reasons that we retired most of these Notes is that the conversion rate adjusts with each quarterly dividend payment potentially resulting in more dilution to our shareholders. With the retirement of most of these Notes, we were able to mitigate some of that potential dilution. |
New 4% Convertible Notes
• | Also in February, we sold $300 million in principal of new 4.00% Convertible Notes due February 1, 2018. The conversion rate on these new Notes is of 109.1048 shares of common stock per $1,000 principal or $9.17 per share. In addition, we have implemented a bond hedge that effectively increases the conversion rate to $10.36 per share. Unlike the 2.875% Convertible Notes, these new Notes do not adjust for dividends of up to $0.15 per quarter - our dividend rate for the last four years. |
Updates on Approved Royalty Bearing Products
Avastin® (bevacizumab):
• | On January 30, 2014, Genentech/Roche reported that 2013 worldwide sales increased by 13% year over year. |
◦ | There was significant increase in sales in US in colorectal cancer due to label expansion through multiple lines of therapy. |
◦ | Strong sales in EU were driven by ovarian and colorectal cancers with the latter due to the label expansion through multiple lines of therapy. |
◦ | Steady growth in Japan in colorectal cancer, breast cancer and non-small cell lung cancer. |
Page 1
PDL BioPharma, Inc.
Q4-Year End 2013
March 3, 2014
• | On July 25, 2013, Genentech/Roche stated that it intends to file for approval for treatment of cervical cancer in US and EU in 2014. |
• | On December 12, 2012 and January 24, 2013, Genentech/Roche announced EU and US approval, respectively for second line metastatic colorectal cancer. |
Herceptin® (trastuzumab):
• | On January 30, 2014, Genentech/Roche reported that 2013 worldwide sales increased by 6% year over year with volume growth driven by Asia and Latin America. |
• | On September 2, 2013, Genentech/Roche said European Commission approved a subcutaneous formulation of Herceptin to treat HER2-positive breast cancer. |
◦ | Subcutaneous administration takes 2-5 minutes instead of 30-90 minutes with the approved IV administration. |
Lucentis® (ranibizumab):
• | On January 30, 2014, Genentech/Roche reported that 2013 US sales increased by 15% year over year. |
◦ | Less frequent than monthly dosing regimen is stabilizing market share in AMD. |
◦ | Increasing share in RVO and DME markets. |
• | On January 29, 2013, Novartis reported that 2013 ex-US sales were $2.38 billion, up 1% year over year. |
Tysabri® (natalizumab):
• | On January 29, 2014, Biogen Idec reported that global sales in 2013 were $1.5 billion. |
Xolair® (omalizumab):
• | On January 30, 2014, Genentech/Roche reported that 2013 US sales increased by 13% year over year. |
• | On January 29, 2014, Novartis reported that 2013 ex-US sales were $613 million, up 24% year over year. |
• | On January 24, 2014, Novartis reported that the EMA Committee for Medicinal Products had adopted a positive opinion for the use of Xolair as an add on therapy for chronic spontaneous idiopathic urticaria. |
• | On October 10, 2013, Genentech/Roche announced that the FDA had accepted for filing the US approval application for chronic idiopathic urticaria (CIU) with a PDUFA date in second quarter of 2014. |
• | On June 26, 2013, Novartis announced that the second Phase 3 trial in 335 patients ages 12-75 with moderate to severe refractory chronic idiopathic urticaria (CIU) treated with 300 mg subcutaneous Xolair given every 4 weeks for 24 weeks as an add-on to antihistamine therapy met the primary efficacy endpoint with a similar incidence and severity of adverse events between treated and placebo patients. |
◦ | In February 2013, Novartis reported data from the first Phase 3 in 323 patients ages 12-75 with moderate to severe refractory CIU showing that 150 and 300 mg doses of Xolair as an add-on to antihistamine therapy each met the primary efficacy endpoint. |
Actemra® (tocilizumab):
• | On January 30, 2014, Genentech/Roche reported that 2013 worldwide sales increased by 30% year over year. |
◦ | Sales growth was driven by monotherapy use with the US being the biggest contributor to growth. |
• | On December 20, 2013, Genentech/Roche announced positive CHMP opinion in EU with respect to approval of the subcutaneous formulation. |
• | On October 21, 2013, Genentech/Roche announced approval of the subcutaneous formulation in the US. |
Perjeta® (pertuzumab):
• | On January 30, 2014, Genentech/Roche reported 2013 worldwide sales increased by 498% year over year. |
◦ | Genentech/Roche announced EMA approval in March 2013. |
◦ | Sales growth driven by metastatic breast cancer with continued increase in first line HER2-positive metastatic breast cancer. |
• | On September 30, 2013, Genentech/Roche announced that FDA had granted accelerated approval for the neo-adjuvant indication. |
Page 2
PDL BioPharma, Inc.
Q4-Year End 2013
March 3, 2014
Kadcyla® (TDM-1 or ado-trastuzumab emtansine):
• | On January 30, 2014, Genentech/Roche reported 2013 worldwide sales of CHF 234 million. |
◦ | Strong uptake in second line treatment of HER2-positive metastatic breast cancer in US. |
◦ | Product launched in some EU countries. |
• | On July 25, 2013, Genentech/Roche announced that a Phase 3 trial comparing Kadcyla to the physician's choice of treatment in patients with HER2-positive breast cancer who have already been treated with a HER2-targeted therapy, met its co-primary endpoint of progression free survival. The other endpoint is overall survival, but these data are not yet mature. |
Gazyva™ (Obinutuzumab or GA101):
• | On November 1, 2013, Genentech/Roche announced that Gazyva™ (obinutuzumab), formerly known as GA101, became the first therapy approved through the FDA’s breakthrough therapy designation, indicated in combination with chlorambucil to treat previously untreated chronic lymphocytic leukemia (CLL). |
◦ | Much earlier than PDUFA date of December 20, 2013. |
◦ | Genentech/Roche expect Gazyva to be on the market shortly. |
◦ | On May 15, 2013, Genentech/Roche announced approval applications for the treatment of CLL had been submitted to European Medicines Association. |
◦ | PDL expects to receive royalties beginning in 1Q14. |
• | On November 7, 2013, Genentech/Roche announced that the results from Stage 2 of Phase 3 trial showed CLL patients treated with Gazyva + chlorambucil had a median progression free survival (PFS) of 26.7 months compared to 15.2 months for patients receiving Rituxan + chlorambucil. |
◦ | Previously, Genentech/Roche announced that results from Stage 1 of same Phase 3 trial showed CLL patients treated with Gazyva + chlorambucil had a PFS of 23 months compared to 10.9 months for patients treated with chlorambucil only. |
Forward-looking Statements
This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new income generating assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward looking statement except as required by law.
Page 3
PDL BioPharma, Inc.
Q4-Year End 2013
March 3, 2014
Royalty Revenue by Product ($ in 000's) * | ||||||||||
Avastin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 33,234 | 46,720 | 32,224 | 32,287 | 144,464 | |||||
2012 | 23,215 | 41,670 | 25,955 | 30,041 | 120,882 | |||||
2011 | 22,283 | 41,967 | 23,870 | 22,886 | 111,006 | |||||
2010 | 16,870 | 44,765 | 29,989 | 24,922 | 116,547 | |||||
2009 | 13,605 | 35,161 | 21,060 | 15,141 | 84,966 | |||||
2008 | 9,957 | 30,480 | 19,574 | 12,394 | 72,405 | |||||
2007 | 8,990 | 21,842 | 17,478 | 9,549 | 57,859 | |||||
2006 | 10,438 | 15,572 | 15,405 | 12,536 | 53,952 | |||||
Herceptin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 30,287 | 47,353 | 30,961 | 33,038 | 141,640 | |||||
2012 | 25,702 | 44,628 | 30,433 | 28,307 | 129,070 | |||||
2011 | 25,089 | 42,209 | 31,933 | 21,812 | 121,042 | |||||
2010 | 23,402 | 38,555 | 27,952 | 25,441 | 115,350 | |||||
2009 | 16,003 | 32,331 | 26,830 | 18,615 | 93,779 | |||||
2008 | 14,092 | 34,383 | 28,122 | 20,282 | 96,880 | |||||
2007 | 19,035 | 28,188 | 22,582 | 14,802 | 84,608 | |||||
2006 | 15,142 | 19,716 | 21,557 | 20,354 | 76,769 | |||||
Lucentis | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 12,032 | 30,066 | 13,536 | 12,127 | 67,760 | |||||
2012 | 10,791 | 27,938 | 12,552 | 11,097 | 62,377 | |||||
2011 | 8,878 | 24,313 | 12,157 | 10,750 | 56,099 | |||||
2010 | 7,220 | 19,091 | 10,841 | 8,047 | 45,198 | |||||
2009 | 4,621 | 12,863 | 8,123 | 6,152 | 31,759 | |||||
2008 | 3,636 | 11,060 | 7,631 | 4,549 | 26,876 | |||||
2007 | 2,931 | 6,543 | 6,579 | 3,517 | 19,570 | |||||
2006 | — | — | 289 | 3,335 | 3,624 | |||||
Xolair | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 5,930 | 10,025 | 7,334 | 7,330 | 30,619 | |||||
2012 | 5,447 | 8,609 | 6,504 | 6,145 | 26,705 | |||||
2011 | 4,590 | 7,621 | 5,916 | 5,823 | 23,949 | |||||
2010 | 3,723 | 6,386 | 4,980 | 4,652 | 19,741 | |||||
2009 | 2,665 | 5,082 | 4,085 | 3,722 | 15,553 | |||||
2008 | 1,488 | 4,866 | 3,569 | 2,927 | 12,850 | |||||
2007 | 1,684 | 3,942 | 3,332 | 2,184 | 11,142 | |||||
2006 | 2,263 | 2,969 | 3,041 | 2,495 | 10,768 | |||||
Perjeta | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 340 | 1,414 | 748 | 879 | 3,381 | |||||
2012 | — | — | 58 | 250 | 308 | |||||
2011 | — | — | — | — | — | |||||
2010 | — | — | — | — | — | |||||
2009 | — | — | — | — | — | |||||
2008 | — | — | — | — | — | |||||
2007 | — | — | — | — | — | |||||
2006 | — | — | — | — | — | |||||
Kadcyla | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | — | 551 | 830 | 859 | 2,240 | |||||
2012 | — | — | — | — | — | |||||
2011 | — | — | — | — | — | |||||
2010 | — | — | — | — | — | |||||
2009 | — | — | — | — | — | |||||
2008 | — | — | — | — | — | |||||
2007 | — | — | — | — | — | |||||
2006 | — | — | — | — | — | |||||
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 12,965 | 13,616 | 11,622 | 12,100 | 50,304 | |||||
2012 | 11,233 | 12,202 | 11,749 | 12,255 | 47,439 | |||||
2011 | 9,891 | 10,796 | 11,588 | 11,450 | 43,725 | |||||
2010 | 8,791 | 8,788 | 8,735 | 9,440 | 35,754 | |||||
2009 | 6,656 | 7,050 | 7,642 | 8,564 | 29,912 | |||||
2008 | 3,883 | 5,042 | 5,949 | 6,992 | 21,866 | |||||
2007 | 839 | 1,611 | 2,084 | 2,836 | 7,370 | |||||
2006 | — | — | — | 237 | 237 | |||||
Actemra | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 2,631 | 2,816 | 2,939 | 3,744 | 12,131 | |||||
2012 | 1,705 | 2,074 | 2,145 | 2,462 | 8,385 | |||||
2011 | 913 | 1,136 | 1,401 | 1,460 | 4,910 | |||||
2010 | 1,587 | 237 | 315 | 688 | 2,827 | |||||
2009 | 585 | 537 | 909 | 1,197 | 3,228 | |||||
2008 | 44 | — | 146 | 369 | 559 | |||||
2007 | 32 | — | — | 17 | 49 | |||||
2006 | — | — | — | — | — | |||||
* As reported to PDL by its licensees | ||||||||||
Totals may not sum due to rounding | ||||||||||
Page 4
PDL BioPharma, Inc.
Q4-Year End 2013
March 3, 2014
Reported Net Sales Revenue by Product ($ in 000's) * | ||||||||||
Avastin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 1,653,108 | 1,694,678 | 1,746,135 | 1,819,877 | 6,913,798 | |||||
2012 | 1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | 6,290,788 | |||||
2011 | 1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | 6,231,255 | |||||
2010 | 1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 6,344,605 | |||||
2009 | 1,345,487 | 1,295,536 | 1,439,730 | 1,514,053 | 5,594,806 | |||||
2008 | 980,715 | 1,084,930 | 1,180,427 | 1,239,382 | 4,485,454 | |||||
2007 | 678,068 | 746,587 | 797,013 | 875,084 | 3,096,752 | |||||
2006 | 439,318 | 516,052 | 570,551 | 592,897 | 2,118,817 | |||||
Herceptin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 1,681,574 | 1,744,145 | 1,681,860 | 1,726,551 | 6,834,130 | |||||
2012 | 1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | 6,454,759 | |||||
2011 | 1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | 6,027,211 | |||||
2010 | 1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 5,330,602 | |||||
2009 | 1,210,268 | 1,133,993 | 1,226,435 | 1,278,626 | 4,849,323 | |||||
2008 | 1,105,426 | 1,195,215 | 1,211,982 | 1,186,806 | 4,699,428 | |||||
2007 | 891,761 | 949,556 | 979,602 | 1,015,033 | 3,835,952 | |||||
2006 | 529,585 | 659,719 | 761,099 | 803,576 | 2,753,979 | |||||
Lucentis | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 1,203,179 | 1,171,423 | 1,200,791 | 1,212,651 | 4,788,045 | |||||
2012 | 1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | 4,372,871 | |||||
2011 | 887,757 | 943,418 | 1,052,809 | 1,075,015 | 3,958,999 | |||||
2010 | 721,967 | 698,890 | 745,376 | 804,684 | 2,970,917 | |||||
2009 | 462,103 | 469,736 | 555,296 | 615,212 | 2,102,347 | |||||
2008 | 363,615 | 393,682 | 460,167 | 454,922 | 1,672,386 | |||||
2007 | 224,820 | 219,579 | 299,995 | 322,300 | 1,066,695 | |||||
2006 | — | — | 10,689 | 157,742 | 168,431 | |||||
Xolair | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 341,309 | 365,778 | 391,900 | 401,333 | 1,500,321 | |||||
2012 | 310,234 | 314,638 | 347,796 | 340,431 | 1,313,100 | |||||
2011 | 267,754 | 277,642 | 310,874 | 314,911 | 1,171,182 | |||||
2010 | 228,859 | 225,878 | 251,055 | 263,389 | 969,179 | |||||
2009 | 184,669 | 181,086 | 211,006 | 219,693 | 796,454 | |||||
2008 | 137,875 | 169,521 | 177,179 | 183,753 | 668,329 | |||||
2007 | 129,172 | 130,700 | 144,250 | 147,754 | 551,876 | |||||
2006 | 95,241 | 99,354 | 112,608 | 118,002 | 425,204 | |||||
Perjeta | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 34,008 | 55,076 | 66,353 | 87,949 | 243,386 | |||||
2012 | — | — | 5,080 | 25,000 | 30,079 | |||||
2011 | — | — | — | — | — | |||||
2010 | — | — | — | — | — | |||||
2009 | — | — | — | — | — | |||||
2008 | — | — | — | — | — | |||||
2007 | — | — | — | — | — | |||||
2006 | — | — | — | — | — | |||||
Kadcyla | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | — | 21,459 | 73,626 | 85,906 | 180,991 | |||||
2012 | — | — | — | — | — | |||||
2011 | — | — | — | — | — | |||||
2010 | — | — | — | — | — | |||||
2009 | — | — | — | — | — | |||||
2008 | — | — | — | — | — | |||||
2007 | — | — | — | — | — | |||||
2006 | — | — | — | — | — | |||||
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 434,677 | 451,358 | 387,407 | 403,334 | 1,676,776 | |||||
2012 | 374,430 | 401,743 | 391,623 | 408,711 | 1,576,508 | |||||
2011 | 329,696 | 356,876 | 388,758 | 381,618 | 1,456,948 | |||||
2010 | 293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 | |||||
2009 | 221,854 | 229,993 | 257,240 | 285,481 | 994,569 | |||||
2008 | 129,430 | 163,076 | 200,783 | 233,070 | 726,359 | |||||
2007 | 30,468 | 48,715 | 71,972 | 94,521 | 245,675 | |||||
2006 | — | — | — | 7,890 | 7,890 | |||||
Actemra | Q1 | Q2 | Q3 | Q4 | Total | |||||
2013 | 87,703 | 91,374 | 97,961 | 124,815 | 401,852 | |||||
2012 | 56,662 | 66,624 | 71,505 | 82,053 | 276,843 | |||||
2011 | 30,433 | 35,370 | 46,709 | 48,671 | 161,183 | |||||
2010 | 52,908 | 5,405 | 10,493 | 22,919 | 91,725 | |||||
2009 | 19,504 | 17,920 | 30,313 | 39,888 | 107,625 | |||||
2008 | 1,452 | 1,377 | 5,981 | 12,305 | 21,115 | |||||
2007 | — | — | — | 1,137 | 1,137 | |||||
2006 | — | — | — | — | — | |||||
* As reported to PDL by its licensee. Dates in above charts | ||||||||||
reflect when PDL receives royalties on sales. Sales occurred | ||||||||||
in the quarter prior to the dates in the above charts. | ||||||||||
Totals may not sum due to rounding | ||||||||||
Page 5
PDL BioPharma, Inc.
Q4-Year End 2013
March 3, 2014
Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) * | ||||||||||||||
Avastin Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | 724,483 | 679,914 | 710,501 | 664,109 | 750,491 | 716,337 | 765,636 | |||||||
US Made & ex-US Sold | 532,979 | 428,976 | 281,905 | 161,369 | 165,651 | 360,177 | 349,836 | |||||||
ex-US Made & Sold | 316,265 | 442,437 | 670,572 | 827,629 | 778,536 | 669,621 | 704,405 | |||||||
Total | 1,573,727 | 1,551,327 | 1,662,977 | 1,653,108 | 1,694,678 | 1,746,135 | 1,819,877 | |||||||
US Made & Sold | 46 | % | 44 | % | 43 | % | 40 | % | 44 | % | 41 | % | 42 | % |
US Made & ex-US Sold | 34 | % | 28 | % | 17 | % | 10 | % | 10 | % | 21 | % | 19 | % |
ex-US Made & Sold | 20 | % | 29 | % | 40 | % | 50 | % | 46 | % | 38 | % | 39 | % |
Herceptin Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | 497,109 | 503,612 | 515,790 | 514,113 | 583,677 | 518,790 | 561,990 | |||||||
US Made & ex-US Sold | 466,477 | 545,625 | 552,127 | 486,400 | 563,243 | 522,159 | 383,439 | |||||||
ex-US Made & Sold | 661,727 | 614,459 | 582,578 | 681,060 | 597,225 | 640,911 | 781,123 | |||||||
Total | 1,625,313 | 1,663,695 | 1,650,495 | 1,681,574 | 1,744,145 | 1,681,860 | 1,726,551 | |||||||
US Made & Sold | 31 | % | 30 | % | 31 | % | 31 | % | 33 | % | 31 | % | 33 | % |
US Made & ex-US Sold | 29 | % | 33 | % | 33 | % | 29 | % | 32 | % | 31 | % | 22 | % |
ex-US Made & Sold | 41 | % | 37 | % | 35 | % | 41 | % | 34 | % | 38 | % | 45 | % |
Lucentis Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | 412,131 | 385,746 | 381,592 | 392,207 | 419,030 | 449,834 | 461,380 | |||||||
US Made & ex-US Sold | 674,411 | 711,795 | 728,103 | 810,972 | 752,393 | 750,958 | 751,271 | |||||||
ex-US Made & Sold | — | — | — | — | — | — | — | |||||||
Total | 1,086,543 | 1,097,541 | 1,109,695 | 1,203,179 | 1,171,423 | 1,200,791 | 1,212,651 | |||||||
US Made & Sold | 38 | % | 35 | % | 34 | % | 33 | % | 36 | % | 37 | % | 38 | % |
US Made & ex-US Sold | 62 | % | 65 | % | 66 | % | 67 | % | 64 | % | 63 | % | 62 | % |
ex-US Made & Sold | — | % | — | % | — | % | — | % | — | % | — | % | — | % |
Xolair Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | 193,600 | 211,702 | 210,892 | 207,976 | 218,860 | 236,180 | 242,991 | |||||||
US Made & ex-US Sold | — | — | — | — | — | — | — | |||||||
ex-US Made & Sold | 121,039 | 136,094 | 129,540 | 133,333 | 146,918 | 155,720 | 158,342 | |||||||
Total | 314,638 | 347,796 | 340,431 | 341,309 | 365,778 | 391,900 | 401,333 | |||||||
US Made & Sold | 62 | % | 61 | % | 62 | % | 61 | % | 60 | % | 60 | % | 61 | % |
US Made & ex-US Sold | — | % | — | % | — | % | — | % | — | % | — | % | — | % |
ex-US Made & Sold | 38 | % | 39 | % | 38 | % | 39 | % | 40 | % | 40 | % | 39 | % |
Perjeta Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | — | 5,080 | 24,571 | 32,377 | 48,979 | 49,111 | 54,168 | |||||||
US Made & ex-US Sold | — | — | 428 | 1,632 | 6,096 | 17,242 | 33,781 | |||||||
ex-US Made & Sold | — | — | — | — | — | — | — | |||||||
Total | — | 5,080 | 25,000 | 34,008 | 55,076 | 66,353 | 87,949 | |||||||
US Made & Sold | — | % | 100 | % | 98 | % | 95 | % | 89 | % | 74 | % | 62 | % |
US Made & ex-US Sold | — | % | — | % | 2 | % | 5 | % | 11 | % | 26 | % | 38 | % |
ex-US Made & Sold | — | % | — | % | — | % | — | % | — | % | — | % | — | % |
Kadcyla Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | — | — | — | — | 21,459 | 72,887 | 82,395 | |||||||
US Made & ex-US Sold | — | — | — | — | — | 739 | 3,510 | |||||||
ex-US Made & Sold | — | — | — | — | — | — | — | |||||||
Total | — | — | — | — | 21,459 | 73,626 | 85,906 | |||||||
US Made & Sold | — | % | — | % | — | % | — | % | 100 | % | 99 | % | 96 | % |
US Made & ex-US Sold | — | % | — | % | — | % | — | % | — | % | 1 | % | 4 | % |
ex-US Made & Sold | — | % | — | % | — | % | — | % | — | % | — | % | — | % |
Total Sales | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 | 2013 - Q3 | 2013 - Q4 | |||||||
US Made & Sold | 1,827,323 | 1,786,053 | 1,843,345 | 1,810,783 | 2,042,496 | 2,043,139 | 2,168,559 | |||||||
US Made & ex-US Sold | 1,673,867 | 1,686,395 | 1,562,564 | 1,460,373 | 1,487,383 | 1,651,276 | 1,521,837 | |||||||
ex-US Made & Sold | 1,099,031 | 1,192,990 | 1,382,690 | 1,642,023 | 1,522,679 | 1,466,252 | 1,643,870 | |||||||
Total | 4,600,221 | 4,665,438 | 4,788,598 | 4,913,178 | 5,052,559 | 5,160,667 | 5,334,267 | |||||||
US Made & Sold | 40 | % | 38 | % | 38 | % | 37 | % | 40 | % | 40 | % | 41 | % |
US Made & ex-US Sold | 36 | % | 36 | % | 33 | % | 30 | % | 29 | % | 32 | % | 29 | % |
ex-US Made & Sold | 24 | % | 26 | % | 29 | % | 33 | % | 30 | % | 28 | % | 31 | % |
* As reported to PDL by its licensee. Dates in above charts | ||||||||||||||
reflect when PDL receives royalties on sales. Sales occurred | ||||||||||||||
in the quarter prior to the dates in the above charts. | ||||||||||||||
Totals may not sum due to rounding | ||||||||||||||
Page 6